Piramal Pharma cash flow

Latest FY26

Cash from operations: ₹1,653cr+85.2% on FY25
Capital spending: ₹890cr+34.0% on FY25
Free cash flow: ₹763cr+234.6% on FY25
Cash from financing: −₹39.0cr−₹441 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	831	816	741	677
	—	341	422	448	344
	—	−5.2	−10.4	−11.9	0.0
	—	−12.2	−7.1	4.8	−1.0
	—	41.7	48.0	27.5	0.0
	—	184	31.6	48.3	71.6
	—	189	72.6	22.1	50.6
	—	0.0	0.0	0.0	0.5
	—	−798	−197	−532	−173
	—	217	−233	−391	89.3
	—	−22.7	−26.4	18.9	76.3
	—	−19.6	0.1	0.7	76.7
	—	6.6	−36.5	20.8	13.9
	—	13.8	−7.2	2.4	−137
	—	778	18.2	404	−265
	—	12.4	74.8	29.8	44.1
	—	0.0	0.0	−5.0	−24.1
	—	314	−108	183	0.0
	—	−7.9	20.8	22.7	0.0
	—	−0.6	−0.7	4.4	0.4
	—	33.0	8.1	6.8	2.5
Cash from operating activities
	−37.8	−233	342	120	−174
	—	2,096	885	1,045	847
	—	1,863	1,227	1,165	673
	—	0.0	0.0	−3.8	0.0
	—	210	334	157	189
	—	1,653	892	1,005	484
Cash from investing activities
	—	890	664	712	965
	—	13.4	5.3	1.6	19.7
	—	2.2	0.0	0.0	0.0
	—	992	1,872	1,671	1,209
	—	888	1,999	1,943	834
	—	0.0	0.0	0.0	20.4
	—	37.7	46.3	22.1	75.4
	—	5.6	0.0	0.0	0.0
	—	109	8.3	−18.0	−73.7
	—	−826	−477	−434	−1,339
Cash from financing activities
	—	0.0	0.0	1,050	0.0
	—	2.8	0.0	0.0	0.0
	—	0.0	0.0	14.1	0.0
	—	1,887	4,660	1,661	4,385
	—	1,567	4,611	2,632	3,186
	—	47.3	36.7	24.9	42.6
	—	296	438	0.0	271
	—	18.6	14.5	0.0	67.0
	—	0.0	0.0	−462	0.0
	—	−39.0	−441	−422	818
	—	788	−26.0	148	−37.1
	—	6.4	−10.9	17.8	5.2
	—	794	−36.9	166	−32.0
	—	—	—	219	53.2
Reference items
	1,200	922	1,445	1,196	628
	12.3%	10.4%	15.8%	14.6%	8.9%
	763	763	228	293	−481
	—	1,241	−49.1	—	—
	₹5.75	₹5.75	₹1.72	₹2.20	−₹3.62
	40.16×	—	—	—	—
	—	−5.07×	9.79×	56.37×	−2.60×
	—	210	334	157	189
	—	296	438	—	271

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

PPLPHARMA₹230.78

Piramal Pharma Ltd.

· Pharma & Health

₹ CrorePeersDIVISLAB SYNGENE GLAND WOCKPHARMA ASTERDM COHANCE LALPATHLAB NATCOPHARMMcap ₹30,628 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	676.7	740.6	816.3	831.2	—
+ Finance Costs	344.2	448.5	421.6	340.8	—
+ Interest Income	0.0	-11.9	-10.4	-5.2	—
+ Fair Value (Gains) / Losses	-1.0	4.8	-7.1	-12.2	—
+ Share-based Payments	0.0	27.5	48.0	41.7	—
+ Unrealised FX (Gain) / Loss	71.6	48.3	31.6	184.3	—
+ Other Non-cash Items	50.6	22.1	72.6	188.8	—
+ Other Reconciling Items	0.5	0.0	0.0	0.0	—
Changes in Working Capital
+ Inventories	-172.6	-531.8	-197.1	-798.1	—
+ Trade Receivables — Current	89.3	-391.4	-233.5	217.2	—
+ Other Financial Assets — Current	76.3	18.9	-26.4	-22.7	—
+ Other Financial Assets — Non-current	76.7	0.7	0.1	-19.6	—
+ Other Current Assets	13.9	20.8	-36.5	6.6	—
+ Other Non-current Assets	-136.8	2.4	-7.2	13.8	—
+ Trade Payables — Current	-264.7	404.3	18.2	778.0	—
+ Other Financial Liabilities — Current	44.1	29.8	74.8	12.4	—
+ Other Financial Liabilities — Non-current	-24.1	-5.0	0.0	0.0	—
+ Other Current Liabilities	0.0	183.2	-108.3	314.4	—
+ Other Non-current Liabilities	0.0	22.7	20.8	-7.9	—
+ Provisions — Current	0.4	4.4	-0.7	-0.6	—
+ Provisions — Non-current	2.5	6.8	8.1	33.0	—
Cash from Operating Activities
Profit Before Tax (per I/S)	-174.5	119.8	341.7	-233.3	-37.8
+ Total Adjustments (incl. Working Capital)	847.4	1,045.4	885.0	2,096.0	—
Cash from Operations (pre-tax)	672.9	1,165.2	1,226.7	1,862.7	—
+ Other Inflows / (Outflows) — Operating	0.0	-3.8	0.0	0.0	—
+ Income Taxes Paid	189.0	156.8	334.4	210.2	—
Cash from Operating Activities	483.9	1,004.5	892.3	1,652.6	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	964.8	712.0	664.4	890.0	—
+ Disp of Fixed Assets	19.7	1.6	5.3	13.4	—
+ Disp of Other Long-term Assets	0.0	0.0	0.0	2.2	—
+ Purchase of Investments (Equity / Debt)	1,209.1	1,670.7	1,872.4	991.7	—
+ Sale of Investments (Equity / Debt)	834.0	1,943.1	1,999.5	887.9	—
+ Investment in Partnership Firms / LLPs	20.4	0.0	0.0	0.0	—
+ Dividends Received — Investing	75.4	22.1	46.3	37.7	—
+ Interest Received — Investing	0.0	0.0	0.0	5.6	—
+ Other Inflows / (Outflows) — Investing	-73.7	-18.0	8.3	108.7	—
Cash from Investing Activities	-1,338.8	-434.0	-477.5	-826.0	—
Cash from Financing Activities
+ Proceeds from Issue of Shares	0.0	1,050.0	0.0	0.0	—
+ Proceeds from Exercise of Stock Options	0.0	0.0	0.0	2.8	—
+ Buyback / Redemption of Own Shares	0.0	14.1	0.0	0.0	—
+ Proceeds from Borrowings	4,384.7	1,660.7	4,659.9	1,887.4	—
+ Repayment of Borrowings	3,186.3	2,632.2	4,611.2	1,567.0	—
+ Payment of Lease Liabilities	42.6	24.9	36.7	47.3	—
+ Interest Paid	271.0	0.0	438.4	296.4	—
+ Dividends Paid	67.0	0.0	14.5	18.6	—
+ Other Inflows / (Outflows) — Financing	0.0	-461.8	0.0	0.0	—
Cash from Financing Activities	817.8	-422.4	-440.8	-39.0	—
Net Changes in Cash (pre-FX)	-37.1	148.2	-26.0	787.6	—
+ Effect of FX Rate Changes on Cash	5.2	17.8	-10.9	6.4	—
Net Changes in Cash	-32.0	166.0	-36.9	793.9	—
Closing Cash	53.2	219.2	—	—	—
Reference Items
EBITDA	628.2	1,196.3	1,444.8	921.6	1,200.2
EBITDA Margin %	8.87	14.64	15.79	10.39	12.27
Free Cash Flow (CFO − Capex)	-480.9	292.5	227.9	762.6	762.6
Free Cash Flow to Equity	—	—	-49.1	1,241.4	—
Free Cash Flow per Basic Share	-3.62	2.20	1.72	5.75	5.75
Price to Free Cash Flow	—	—	—	—	40.16
Cash Flow to Net Income	-2.60	56.37	9.79	-5.07	—
Cash Paid for Taxes	189.0	156.8	334.4	210.2	—
Cash Paid for Interest	271.0	—	438.4	296.4	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.